Company intelligence / Profile preview

Generium

Volginskiy, Vladimirskaya oblast, Russia

Ownership: Private
Employees: ~1700
Development stage: Phase 3

Overview

Generium leads the Russian orphan pharmaceutical market with several biotechnological drugs for rare diseases already approved or in late-stage development. The company has launched biosimilars such as Genolar and supplies products internationally. It maintains high standards of quality control throughout R&D and production processes[1][4][7].

Therapeutic areas: OphthalmologyOncologyImmunologyRare Diseases
Modalities: Monoclonal antibodies (mAbs)Gene therapyBiosimilarsRecombinant proteins[1][5]
Industry: Biotech

Drug pipeline

15 assets

verenafusp alfa

14 more assets in the full pipeline.

Request access →

Partnerships

Selexis SA – partnership for biosimilar development including Genolar® launch in Russia [4]

Beyond the preview

Go deeper on Generium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Generium.

Explore the full profile